

ALLEGATO B

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n._1_ posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale _05/H1 Anatomia Umana____ , settore scientifico-disciplinare _____BIO/16 - Anatomia Umana____ presso il Dipartimento di _____Bioscienze_____, (avviso bando pubblicato sulla G.U. n. __7__ del __25.01.2019__) Codice concorso __3961__

Mattia Volta CURRICULUM VITAE

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	VOLTA
NOME	MATTIA
DATA DI NASCITA	21/05/1983

INSERIRE IL PROPRIO CURRICULUM (non eccedente le 30 pagine)

EDUCATION

Jul 2011 - Dec 2011 University of British Columbia, Vancouver, BC, Canada
Visiting scholar at the Centre for Applied Neurogenetics under supervision of Prof. Matthew Farrer

2009 to 2011 University of Ferrara, Italy
Dept. of Experimental and Clinical Medicine, Section of Pharmacology

- Position: PhD Student in Molecular Pharmacology
- Research Projects: opioids and parkinsonism; LRRK2 and parkinsonism.

Supervised by Prof. M. Morari (University of Ferrara, Italy)
PhD received on March 8th, 2012.

Dec 2008 University of Ferrara, Italy
State exam for certificate of pharmacist profession (208/250)

Jul 2008 University of Ferrara, Italy
Degree in **Pharmaceutical Chemistry**, faculty of Pharmacy (110/110 summa cum laude).

- Lab Project: Efficacy of delta opioid receptor ligands in an animal model of parkinsonism: functional analysis of the neuronal circuitry.

Supervised by Prof. M. Morari

1997-2002 Liceo Scientifico Statale (High School) A. Roiti, Ferrara (FE), Italy (100/100).

WORK EXPERIENCE

Sep 2007-March 2008 Pre graduation pharmacy training at "San Martino" Via Chiesa 365, 44100 San Martino

(FE), Italy.

Sep 2008-Dec 2008 **University of Ferrara, Italy**
Department of Experimental and Clinical Medicine, Section of Pharmacology

- Position: Research Assistant.
- Research Project: Evaluation of the antiparkinsonian action and neurochemical effects of NOP receptor antagonists in vivo.

Supervisor Prof. Michele Morari

May 2012 - July 2015 **University of British Columbia, Vancouver, BC, Canada**
Centre for Applied Neurogenetics, Dept. of Medical Genetics

- Position: Post-doctoral Fellow
- Supervisor: Prof. Matthew Farrer

Sep 2015 - current **European Academy of Bolzano, Italy**
Institute for Biomedicine

- Position: Senior Researcher
- Director: Prof. Peter Pramstaller

Skills / Responsibilities / Interests

Skills

Scientific

- neurochemical techniques (in vivo microdialysis with behavioral testing in mice and rats)
- stereotactic surgery: 6-OHDA lesion in mice and rats; microdialysis probe implantation in mice and rats; small molecule administration in specific brain areas
- behavioral studies in mice and rats (rotarod test, bar test, drag test, open field test, cylinder test, novel object location and recognition, Y-maze, puzzle box, tail suspension test, challenging beam test)
- intracardial perfusion of mice and rats
- dissection of discrete brain areas from mice and rats
- raising mouse colonies
- immunohistochemistry
- immunocytochemistry
- basic practical knowledge of electrophysiological recording in primary neuronal cultures and field potential recording in acute brain slices
- basic knowledge of PCR (Polymerase Chain Reaction) technique for mice genotyping
- cell cultures technique
- assessment of brain pathology using Aperio ImageScope software for the quantification of DAB immunostaining
- equipment/technical: use of software for behavioural analysis (Phenotracker, TSE systems); HPLC techniques for the detection of in vivo amino acid (glutamate, GABA) and monoamines (dopamine, serotonin and their metabolites) samples; basic working knowledge of confocal microscope imaging and fluorescence-based; EnVision system (Perkin Elmer) with Calcium 5 and AlphaScreen assay kits; microscopy; basic working knowledge of electrophysiology instrumentation and cell culture patch clamp; basic working knowledge of

the ProteinSimple WES system.

- I. T.**
- Microsoft Word, Excel, PowerPoint
 - GraphPad (scientific graphs and statistic)
 - ImageJ
 - Adobe Illustrator
 - Adobe Photoshop (basic)
 - Cell Profiler
- EndNote
- Clarity (chromatography software)
 - Clampex/Clampfit (electrophysiology software)

Languages English: Trinity College Level 8; First Certificate in English, Grade A (87/100)

Responsibilities

Development of independent line of research
Maintenance of Laboratory.
Supervision and assistance to graduate and undergraduate students.
Development and application of scientific projects.
Writing and commenting manuscripts for scientific publication.
Writing grant and fellowship applications.
Responsibility of scientific research direction

Interests

Academic Opioids and Parkinson's disease
Genetic models of parkinsonism
Molecular mechanisms of neurodegeneration
Autophagy and proteinopathies

Publications

Full papers

- Mabrouk O.S., **Volta M.**, Marti M., Morari M. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism. J. Neurochem. 2008 Dec; 107(6):1647-59.
- **Volta M.**, Marti M., McDonald J., Molinari S, Camarda V, Pelà M, Trapella C and Morari M. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4). Peptides 2010; 31: 1194-1204.
- **Volta M.**, Mabrouk O.S., Bido S., Marti M., Morari M. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. J. Neurochem. 2010; 115: 1543-1555.
- **Volta M.**, Viaro R., Trapella C., Marti M., Morari M. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D₂/D₃ receptors and impact on nigro-thalamic neurons and motor activity. Exp. Neurol. 2011; 228: 126-137.
- Esposito E., Mariani P., Ravani L., Contado C., **Volta M.**, Bido M., Drechsler M., Mazzoni S., Menegatti E., Morari M., Cortesi R. Nanoparticulate lipid dispersions for bromocriptine delivery:

characterization and in vivo study. Eur. J. Pharm. Biopharm. 2012; 80: 306-314.

- Marti M., Mela F., Budri M., **Volta M.**, Malfacini D., Molinari S., Zaveri N.T., Ronzoni S., Petrillo P., Calo' G., Morari M. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist Nik-21273 in comparison with SB-612111. Br. J. Pharmacol. 2013; 168: 863-879.
- Vilariño-Güell C., Rajput A., Milnerwood A.J., Shah B., Szu-Tu C., Trinh J., Yu I., Encarnacion M., Munsie L.N., Tapia L., Gustavsson E.K., Chou P., Tatarnikov I., Evans D.M., Pishotta F.T., **Volta M.**, Beccano-Kelly D., Thompson C., Lin M.K., Sherman H.E., Han H.J., Guenther B.L., Wasserman W.W., Bernard V., Ross C.J., Appel-Cresswell S., Stoessl A.J., Robinson C.A., Dickson D.W., Ross O.A., Wszolek Z.K., Aasly J.O., Wu R.M., Hentati F., Gibson R.A., McPherson P.S., Girard M., Rajput M., Rajput A.H., Farrer M.J. DNAJC13 mutations in Parkinson disease. Hum. Mol. Genet. 2014; 23(7): 1794-1801.
- Milnerwood A.J., Parsons M.P., Young F.B., Singaraja R.R., Franciosi S., **Volta M.**, Bergeron S., Hayden M.R., Raymond L.A. Memory and synaptic deficits in Hip14/DHHC17 knockout mice. Proc. Natl. Acad. Sci USA. 2013; 110 (50): 20296-20301.
- Walker M.D.*, **Volta M.***, Cataldi S., Dinelle K., Beccano-Kelly D., Munsie L., Kornelson R., Mah C., Chou P., Co K., Khinda J., Mroczek M., Bergeron S., Yu K., Cao L.P., Funk N., Ott T., Galter D., Riess O., Biskup S., Milnerwood A.J., Stoessl A.J., Farrer M.J., Sossi V. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. Journal of Parkinson's disease 2014; 4 (3): 483-498. **equal contribution*
- Mabrouk O.S., Viaro R., **Volta M.**, Ledonne A., Mercuri N., Morari M. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism. Journal of Neuroscience 2014; 34(39): 12953-12962.
- Beccano-Kelly D.A., Kuhlmann N., Tatarnikov I., **Volta M.**, Munsie L.N., Chou P., Cao L.P., Han H., Tapia L., Farrer M.J., Milnerwood A.J. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front. Cell. Neurosci. 2014; 8:301.
- Beccano-Kelly D.A.*, **Volta M.***, Munsie L., Paschall S.A., Tatarnikov I., Co K., Chou P., Cao L.P., Bergeron S., Mitchell E., Han H., Melrose H.L., Tapia L., Raymond L.A., Farrer M.J., Milnerwood A.J. LRRK2 overexpression alters presynaptic glutamatergic plasticity, striatal dopamine tone, postsynaptic signal transduction, behavioral activity and long-term memory. Human Molecular Genetics 2015; 24(5):1336-1349. **equal contribution*
- Munsie L.N., Milnerwood A.J., Seibler P., Beccano-Kelly D.A., Tatarnikov I., Khinda J., **Volta M.**, Kadgien C., Cao L.P., Tapia L., Klein C., Farrer M.J. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. Human Molecular Genetics 2015; 24(6):1691-1703.
- **Volta M.**, Milnerwood A.J. and Farrer M.J. Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. The Lancet Neurology 2015; 14(10):1054-1064.
- **Volta M.**, Cataldi S., Beccano-Kelly D., Munsie L., Tatarnikov I., Chou P., Bergeron S., Mitchell E., Lim R., Lloret A., Bennett C.F., Paradiso C., Morari M., Farrer M.J., Milnerwood A.J. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release. Parkinsonism and Related Disorders 2015; 21(10): 1156-1163.
- **Volta M.[#]**, Lavdas A.A., Obergasteiger J., Überbacher C., Picard A., Pramstaller P.P., Hicks A.A., Corti C. Elevated levels of alpha-synuclein blunt cellular signal transduction downstream of Gq protein-coupled receptors. Cellular Signalling 2017; 30:82-91. *#corresponding author*
- **Volta M.[#]**, Melrose H. LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochemical Society Transactions 2017; 45(1): 113-122.

#corresponding author

- Obergasteiger J., Überbacher C., Pramstaller P., Hicks A., Corti C., **Volta M[#]**. CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein. *Biochemical and biophysical Research Communications* 2017; 490(3): 876-881. *#corresponding author*
- **Volta M.^{*}**, Beccano-Kelly D.^{*}, Paschall S., Cataldi S., MacIsaac S., Kuhlmann N., Kadgien C., Tatarnikov I., Fox J., Khinda J., Mitchell E., Bergeron S., Melrose H., Farrer M., Milnerwood A. Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. *eLife* 2017; 6e28377. **equal contribution*
- Pischedda F., Montani C., Obergasteiger J., Frapporti G., Corti C., Rosato-Siri M., **Volta M.**, Piccoli G. Cryopreservation of primary mouse neurons: the benefit of Neurostore cryoprotective medium. *Frontiers in Cellular Neuroscience* 2018; Volume 12, Article 81.
- Obergasteiger J., Frapporti G., Pramstaller P., Hicks A., **Volta M[#]**. A new perspective in Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics. *Molecular Neurodegeneration* 2018; 13:40. *#corresponding author*
- **Volta M[#]**. Signal transduction in Parkinson's disease: modulation of neurotransmission, symptomatology and therapy. In: *Martin & Preedy: The Neuroscience of Parkinson's disease: Genetics, Neurology, Behavior, and Diet* (Book Chapter) In press. *#corresponding author*
- Überbacher C., Obergasteiger J., Venezia S., **Volta M.**, Müller S., Pesce I., Malpeli G., Zoli M., Beccano-Kelly D., Flynn R., Wade-Martins R., Pramstaller P.P., Hicks A.A., Cowley S.A., Corti C. Application of CRISPR/Cas9 editing and digital droplet PCR in human iPSCs to generate novel knock-in reporter lines to visualize dopaminergic neurons. *Stem Cell Research*. Under Revision
- Obergasteiger J., Überbacher C., D'Agostino V., Pischedda F., Piccoli G., Pramstaller P.P., Hicks A.A., **Volta M.[#]**, Corti C.[#] A Parkinson's disease-associated single nucleotide polymorphism in *ATP6V0A1* modifies its transcriptional regulation by alpha-synuclein. *Manuscript under preparation*. *#corresponding authors*

Abstract and relative Conference participation

- Mabrouk OS., **Volta M.**, Marti M., Morari M. Delta Opioid Receptor Stimulation Modifies Pallidal GABAergic Neurotransmission and Improves Motor Performance in 6-Hydroxydopamine Hemilesioned Rats. European Opioid Conference and Neuropeptide Club Joint Meeting, Ferrara (Italy) 9-11 April 2008.
- **Volta M.**, Marti M., Chipilska L., Trapella C., Morari M. Dopamine D2 receptor blockade in substantia nigra pars reticulata modulates behavioral and neurochemical effects evoked by the nociceptin/orphanin FQ receptor antagonist Compound 24 in 6-hydroxydopamine hemilesioned rats. FENS Forum, Amsterdam (The Netherlands) 3-7 July 2010; Poster Number **197.49**.
- **Volta M.**, Mabrouk OS., Bido S., Marti M., Morari M. Short-term nociceptin/orphanin FQ receptor blockade reverses motor impairment and elevation in nigral glutamate release induced by reserpine in mice. 13th International Conference On In Vivo Methods, Brussels (Belgium), 12-16 September 2010; Poster Number **P080**.
- **Volta M.**, Calcagno M., Paradiso C., Longo F., Melrose H., Farrer M.J., Morari M. A parkinsonian-like motor phenotype responsive to dopaminergic agonists in LRRK2-G2019S transgenic mice. SfN Annual Meeting 2011, Washington, DC (USA), 12-16 November 2011; Poster Number **355.22/Z30**.
- **Volta M.**, Calcagno M., Paradiso C., Longo F., Melrose H., Morari M., Farrer MJ. A parkinsonian-like motor phenotype responsive to dopaminergic agonists in LRRK2-G2019S transgenic mice. Canadian Association for Neuroscience annual meeting 2012, Vancouver, BC (Canada), 20-23 May 2012; Poster Number **3-C-99**.
- Milnerwood A., Tapia L., **Volta M.**, Chou P., Vilarino-Guell C., Melrose H., Raymond LA., Farrer MJ. The pathophysiology of Parkinson disease: LRRK2, neurotransmission and synaptic maintenance. Canadian Association for Neuroscience annual meeting 2012, Vancouver, BC (Canada), 20-23 May 2012; Poster Number **2-C-43**.
- **Volta M.**, Milnerwood A., Tapia L., Beccano-Kelly D., Vilarino-Guell C., Co K., Melrose H., Huang A., Yu K., Farrer M.J. Dopamine-dependence of murine LRRK2 associated behaviors. SfN Annual Meeting

2012, New Orleans, LA (USA), 13-17 October 2012; Poster Number **854.03/E67**.

- Beccano-Kelly D., Milnerwood A., Tapia L., **Volta M.**, Chou P., Vilarino-Guell C., Melrose H., Raymond L.A., Farrer M.J. The pathophysiology of Parkinson's disease: LRRK2, neurotransmission and synaptic maintenance. Sfn Annual Meeting 2012, New Orleans, LA (USA), 13-17 October 2012; Poster Number **441.06/E30**.
- Milnerwood A., Tapia L., **Volta M.**, Beccano-Kelly D., Vilarino-Guell C., Farrer M.J. Retromer (VPS35) dysfunction in Parkinson's disease. Sfn Annual Meeting 2012, New Orleans, LA (USA), 13-17 October 2012; Poster Number **854.04/E68**.
- **Volta M.**, Beccano-Kelly D., Tapia L., Vilarino-Guell C., Co K., Chou P., Huang A., Yu K., Bergeron S., Melrose H., Farrer M., Milnerwood A. Dopamine-dependence of murine LRRK2 associated behaviors. Dopamine 2013, Alghero (Italy), 24-28 May 2013; Poster Number **P027**.
- Beccano-Kelly D., **Volta M.**, Co K., Chou P., Tatarnikov I., Cao L.P., Munsie L.N., Tapia L., Melrose H., Raymond L.A., Farrer M.J., Milnerwood A.J. The pathophysiology of Parkinson's disease: LRRK2, neurotransmission and synaptic maintenance. Dopamine 2013, Alghero (Italy), 24-28 May 2013; Poster Number **P018**.
- **Volta M.**, Beccano-Kelly D.A., Munsie L.N., Chou P., Bergeron S., Cataldi S., Tatarnikov I., Co K., Tapia L., Melrose H., Milnerwood A.J., Farrer M.J. The interplay between LRRK2 and the striatal DA system influences behavior in genetic animal models. Sfn Annual Meeting 2013, San Diego, CA (USA), 9-13 November 2013; Poster Number **240.16/M17**.
- Beccano-Kelly D.A., **Volta M.**, Munsie L., Tatarnikov I., Chou P., Co K., Bergeron S., Tapia L., Melrose H., Raymond L.A., Milnerwood A.J., Farrer M.J. Early synaptic alterations in LRRK2 G2019S knock-in mice. Sfn Annual Meeting 2013, San Diego, CA (USA), 9-13 November 2013; Poster Number **240.17/M18**.
- Munsie L.N., Beccano-Kelly D.A., **Volta M.**, Tatarnikov I., Tapia L., Chou P., Khinda J., Vilarino-Guell C., Milnerwood A.J., Farrer M.J. Retromer (VPS35) dysfunction in Parkinson's disease. Sfn Annual Meeting 2013, San Diego, CA (USA), 9-13 November 2013; Poster Number **714.19/H25**.
- **Volta M.**, Bergeron S., Mitchell E., Munsie L., Beccano-Kelly D., Milnerwood A., Farrer M. Exogenous oligomeric alpha-synuclein in LRRK2 transgenic animals. Sfn Annual Meeting 2014, Washington, DC (USA), 15-19 November 2014; Poster Number **410.02/K1**.
- **Volta M.**, Bergeron S., Mitchell E., Cataldi S., MacIsaac S., Munsie L., Beccano-Kelly D., Milnerwood A., Farrer M. Deletion of LRRK2 protects mice from early cognitive impairments induced by alpha-synuclein fibril inoculation. Gordon Research Conference Parkinson's disease 2015, New London, NH (USA), 28 June - 3 July 2015; Poster Number **44**.
- **Volta M.**, Bergeron S., Mitchell E., Cataldi S., MacIsaac S., Beccano-Kelly D., Hicks A., Pramstaller P., Milnerwood A., Farrer M. Deletion of LRRK2 protects mice from early cognitive impairments induced by alpha-synuclein fibril inoculation. SINS 2015, Cagliari (Italy), 8-11 October 2015. **Selected Oral Presentation**.
- **Volta M.**, Beccano-Kelly D., Cataldi S., Paschall S., MacIsaac S., Bergeron S., Co K., Mitchell E., Chou P., Lim R., Paradiso C., Morari M., Farrer M., Milnerwood A. Behavioral and neurochemical analysis of LRRK2 mouse models. Leucine Rich Repeat Kinase 2: Ten Years Along the Road to Therapeutic Intervention". Henley Business School, Greenlands, UK. 11-13 July 2016. **Accepted Selected Oral Communication**.
- Obergasteiger J., Corti C., Lavdas A., Ascione C., Überbacher C., Pramstaller P.P., Hicks A.A., **Volta M.** Functional interaction of the Parkinson's disease risk factor RIT2 with alpha-synuclein. 4th World Parkinson Congress 2016, Portland, OR, USA. 20-23 September 2016; Poster Number **P06.16**.
- **Volta M.**, Obergasteiger J., Corti C., Lavdas A., Ascione C., Überbacher C., Pramstaller P.P., Hicks A.A. Functional interaction of the Parkinson's disease risk factor RIT2 with alpha-synuclein. Sfn Annual Meeting 2016, San Diego, CA (USA), 12-16 November 2016; **Selected Nanosymposium Presentation, Session 013**.
- **Volta M.**, Obergasteiger J., Überbacher C., Ascione C., Frapporti G., Hicks A.A., Pramstaller P.P., Corti C. The novel Parkinson's disease locus RIT2 and alpha-synuclein function in intersecting pathways. International Congress of Parkinson's disease and movement disorders 2017, Vancouver, BC (Canada), 4-8 June 2017; Poster Number **512**.
- **Volta M.**, Obergasteiger J., Frapporti G., Überbacher C., Ascione C., Pramstaller P.P., Rosato-Siri M., Hicks A.A., Corti C. The small GTPase Rin modulates alpha-synuclein inclusions: implications for familial and idiopathic Parkinson's disease. Sfn Annual Meeting 2017, Washington, DC (USA), 11-15 November 2017; **Selected Nanosymposium Presentation, Session 639**.
- **Volta M.**, Obergasteiger J., Castonguay A.M., Frapporti G., Pramstaller P., Hicks A., Corti C., Lévesque M. LRRK2 and alpha-synuclein pathology: role of autophagy and involvement of the small GTPase Rin. Biennial International LRRK2 Meeting, Padova (Italy), 2-4 September 2018. **Selected Oral**

FELLOWSHIPS AND AWARDS

- February 2019** Travel grant from BioTechne to attend the 5th World Parkinson Congress (US\$1000). Kyoto, Japan, 4-7 June 2019
- February 2019** Travel grant from the World Parkinson Coalition to attend the 5th World Parkinson Congress (US\$1600). Kyoto, Japan, 4-7 June 2019
- July 2018** **Research Grant** from Parkinson Canada: Modulation of Rit2 expression to protect against alpha-synuclein neuropathology. CAN\$50.000, 1 year. Role: Co-PI.
- May 2018** Early career travel bursary from the Biochemical Society to attend the Biennial International LRRK2 meeting (GBP 200). Padova, Italy. 2-4 September 2018.
- August 2017** **Research Grant** from the Province of Bolzano on behalf of the Bishop Dr. Karl Golser Foundation: Modulation of alpha-synuclein aggregation: from compound screening to pre-clinical testing in patient-derived cells. €100.000, 1 year. Role: Co-PI.
- August 2016** Travel grant to attend the 4th World Parkinson Congress (US\$1300). Portland, OR, USA. 20-23 September 2016
- May 2016** Early career travel bursary from the Biochemical Society to attend the “Leucine Rich Repeat Kinase 2: Ten Years Along the Road to Therapeutic Intervention” conference (GBP 300). Henley Business School, Greenlands, UK. 11–13 July 2016
- June 2015** Registration support allocated from the Conference Budget for the 2015 Gordon Research Conference on Parkinson’s disease, 28 June-03 July 2015 (US\$820).
- October 2014** Travel award from the University of British Columbia, Faculty of Medicine to attend SfN Annual Meeting 2014 (Washington, DC, USA), 15-19 Nov 2014 (CAN\$ 750).
- August 2014** Recipient of the **Basic Research Fellowship** awarded by Parkinson Society Canada for the period Oct 2014 - Sept 2016 (CAN\$ 50.000/year). *Interrupted after year 1 due to move to out-of-Canada institution.*
- July 2013** Recipient of the **Bluma Tischler post-doctoral fellowship** awarded by the Faculty of Medicine, University of British Columbia (Vancouver, BC, Canada) for the period Sept 2013 - Aug 2014 (CAN\$ 20.400)
- May 2013** Travel grant awarded by Omeros (Seattle, WA, USA) for participation at the Dopamine 2013 conference (Alghero, Italy), 24-28 May 2013 (€500)
- Jul 2011** Travel fellowship awarded by Fondazione Dott. Carlo Fornasini (Poggio Renatico, Italy) to visit Prof. Farrer’s lab at Centre for Applied Neurogenetics (University of British Columbia), Vancouver, BC (Canada), Jul 1st 2011 - Dec 22nd 2011 (€7.500)
- Jul 2010** Travel fellowship awarded by SINS (Italian Society for Neuroscience) to participate at the

SELECTED INVITED SEMINARS

December 13th, 2013 Centre for Biomedicine, Eurac Research; Bolzano (Italy).

January 14th, 2015 Ionis Pharmaceuticals; Carlsbad, CA (USA).

October 30th, 2015 University of Ferrara; Ferrara (Italy).

September 26th, 2016 University of Padova; Padova (Italy).

April 28th, 2017 Aptuit Drug Design and Discovery; Verona (Italy).

June 2nd, 2017 Université Laval; Quebec, QC (Canada).

June 9th, 2017 University of British Columbia; Vancouver, BC (Canada).

September 12th, 2017 University of Oxford; Oxford (United Kingdom).

March 2nd, 2018 University of Milan; Milan (Italy).

October 2nd, 2018 University of Trento; Trento (Italy).

December 13th, 2018 University of Verona; Verona (Italy).

February 5th, 2019 Medical University of Innsbruck; Innsbruck (Austria).

Data

12/02/2019

Luogo

Bolzano